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Abstract
Effects of a nitroxybutylester derivative of aspirin (NCX
4215) on platelet aggregation and prostanoid synthesis were
compared to the effects of aspirin. NCX 4215 was approxi-
mately seven times more potent than aspirin as an inhibitor
of thrombin-induced human platelet aggregation in vitro,
but did not inhibit platelet thromboxane synthesis or gastric
prostaglandin synthesis. NCX 4215 released nitric oxide
when incubated in the presence of platelets and increased
platelet levels of cGMP within 10 min of exposure, while
aspirin did not. The anti-aggregatory effects of NCX 4215
in vitro were significantly attenuated by 10 juM hemoglobin.
In ex vivo studies of ADP- or collagen- or thrombin-induced
rat platelet aggregation, aspirin and NCX 4215 had compa-
rable inhibitory effects 3 h after administration. Aspirin
(10-120 mg/kg) caused extensive hemorrhagic erosion for-
mation in the stomach of the rat within 3 h of oral adminis-
tration, while NCX 4215 did not produce significant damage
at doses of up to 300 mg/kg, nor when given daily for two
weeks at 166 mg/kg. NCX 4215 did not alter systemic arte-
rial blood pressure when administered intravenously to the
rat. These studies demonstrate that NCX 4215 has compara-
ble or enhanced anti-thrombotic activity to that of aspirin,
but does not cause gastric damage or alter systemic blood
pressure. The anti-thrombotic actions of NCX 4215 are, at
least in part, due to generation of nitric oxide. (J. Clin.
Invest. 1995. 96:2711-2718.) Key words: thrombosis * ulcer
* NSAID * platelet aggregation * thromboxane
Introduction
Aspirin is increasingly used for anti-thrombotic prophylaxis,
particularly in patients who have had a myocardial infarction
or angina pectoris, but also in healthy individuals in an attempt
to prevent myocardial infarction (1). The beneficial effects of
aspirin are attributable to its ability to irreversibly inhibit the
enzyme cyclo-oxygenase, thereby preventing the formation of
the pro-aggregatory, vasoconstrictor substance, thromboxane A2
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(2). Because the platelet is unable to generate new cyclo-oxy-
genase, the inhibitory effects of aspirin persist for the 8-1O-d
life span of the platelet. Activation of platelets and their interac-
tion with the vascular endothelium are believed to play a key
role in acute arterial thrombosis (3). Platelet aggregation and
adherence to the blood vessel are promoted by thromboxane
generated by the platelet. Endothelially derived nitric oxide can
inhibit platelet aggregation and adherence, while prostacyclin
can inhibit aggregation (4).
The major limitation to the long-term use of aspirin is the
increased risk of gastrointestinal bleeding, and development or
exacerbation of gastric and duodenal ulcers. Kurata and Abbey
(5) reported that a daily dose of 1000 mg of aspirin increased
the risk of hospitalization for gastric and duodenal ulcers by
approximately eightfold. In a long-term study of every-other-
day aspirin use (325 mg) for prevention of cardiovascular dis-
eases, the incidence of duodenal ulcers was significantly in-
creased above that in the placebo group (6). Even with a dose
of aspirin as low as 100 mg per day, in a study of patients with
coronary artery disease, the prevalence of gastric erosions was
found to be increased (7).
Gastrointestinal ulceration is associated with the use of all
nonsteroidal anti-inflammatory drugs (NSAIDs)' and is directly
related to the ability of these drugs to inhibit cyclo-oxygenase
activity, thereby suppressing the formation of prostaglandins
(8). We recently described a novel series of compounds that
consist of an NSAID (e.g., flurbiprofen, diclofenac, ketoprofen)
linked to a nitric oxide-releasing moiety (9, 10). These "NO-
NSAIDs" exhibit anti-inflammatory activities comparable to
the parent NSAID, but have significantly reduced gastrointesti-
nal toxicity (9-11). NSAIDs, unlike aspirin, are not used as
anti-thrombotics, because they inhibit cyclo-oxygenase activity
in a reversible manner. Thus, platelet thromboxane synthesis
recovers when plasma levels of the NSAID decrease below
those necessary for inhibition of cyclo-oxygenase.
Since the addition of a nitroxybutyl group to several
NSAIDs resulted in a profound reduction in their ability to
produce gastrointestinal injury, we proposed that a similar deri-
vatization of aspirin may yield a compound with anti-thrombotic
activity, but with greater tolerability in the gastrointestinal tract.
In the present study we have compared aspirin to a nitric oxide-
releasing aspirin derivative (NCX 4215; Fig. 1) in terms of
their ability to inhibit platelet aggregation in vitro and ex vivo,
their effects on prostaglandin and thromboxane synthesis and
their ulcerogenic properties in the stomach.
Methods
Animals. Male, Wistar rats (175-200 grams) were obtained from
Charles River Breeding Farms (Montreal, Quebec) and were housed in
1. Abbreviation used in this paper: NSALD, nonsteroidal anti-inflamma-
tory drug.
NO-Releasing Aspirin Derivative 2711
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/95/12/2711/08 $2.00
Volume 96, December 1995, 2711-2718
Acetylsalicylic Acid (ASA)
NCX 4215
I-^OV ON02
Figure 1. Structures of
aspirin and NCX 4215
(acetylsalicylic acid 4-
(nitroxy)butylester).
polypropylene cages and fed standard laboratory chow and tap water
ad libitum. All experimental protocols described in this report were
approved by the Animal Care Committee of the University of Calgary.
Human platelet aggregation. Blood was collected from healthy vol-
unteers (n = 6), who had not ingested aspirin or other nonsteroidal
anti-inflammatory drugs for at least 14 d before donating blood, and
washed platelets (2 x 108 platelets/ml) were prepared as described by
Radomski and Moncada (13). Aliquots (0.4 ml) of the platelets were
added into a cuvette of a dual channel platelet aggregometer (Payton
Instruments, Buffalo, NY) and stirred continuously at 370C. Several
concentrations of thrombin (1-100 U/ml) were tested for their ability
to induce platelet aggregation. The concentration producing 85-95%
maximal aggregation was selected for use in the remainder of the experi-
ment. Aspirin or NCX 4215 was added to the platelet suspensions at
concentrations in the 0.03-5 mM range (always in a volume of 20 [Il)
and 10 min later the platelets were stimulated with thrombin. Aggrega-
tion was monitored for the ensuing 5 min.
An additional series of experiments was performed in which platelets
were preincubated with 10 M'M hemoglobin for 2 min before addition
of aspirin (100 tM), NCX 4215 (100 MM) or vehicle. This concentra-
tion of hemoglobin has previously been shown to prevent nitric oxide-
mediated inhibition of platelet aggregation, while not significantly af-
fecting thrombin-induced platelet aggregation (14). Hemoglobin binds
to and inactivates nitric oxide (15). As a positive control in these
experiments, the effects of incubation of the platelets in the presence
of sodium nitroprusside (100 tM), with or without hemoglobin, was
also assessed.
Nitric oxide generation. Nitric oxide generation from NCX 4215
versus aspirin was examined using chemiluminescence detection of ni-
tric oxide. Washed platelets were prepared as described above. Aliquots
of the platelets (0.4 ml) were incubated in the presence of aspirin
( 1, 10, 100, or 1000 pM) NCX 4215 (same concentrations) or buffer
for 1 or 10 min. To establish whether NCX 4215 could spontaneously
liberate nitric oxide, the drug (1000 ItM) was incubated at 370C for 5
min with buffer in the absence of washed platelets. Incubations were
terminated by centrifugation (1000 g; 5 min) and the cell-free superna-
tant analysed for nitric oxide concentration, as described by Palmer et
al. (16). Briefly, 100 Mll of the sample was injected into a reaction
vessel containing the reducing solution consisting of glacial acetic acid
(5 ml) and potassium iodide (100 Ml of 100 1M). Nitrite present in
the injected buffer was reduced under these conditions to nitric oxide
and the latter stripped from the reducing mixture by bubbling of helium.
Nitric oxide generated was carried by the flow of helium to the nitric
oxide analyzer, where it reacted with ozone, generated internally by
electostatic discharge, and the light emitted measured. The amounts of
nitric oxide detected in mV were convered to nM concentrations using
a nitrite standard curve. These experiments were performed on three
separate preparations of platelets, each time in triplicate.
Platelet cGMP and cAMP concentrations. Washed platelets were
prepared from human blood, as above, and aliquots (0.4 ml) were added
to Eppendorf tubes and placed in a shaking water bath (37TC). Aspirin
(1, 10, 100, or 1000 /.M), NCX 4215 (same concentrations) or vehicle
(methanol) was then added to the platelets as a total volume of 20 pd.
One or ten min later the tubes were centrifuged at 1000 g for 20 s, then
the supernatant was removed. Ice cold phosphate buffer (pH 7.4; 100
pl) was added to the pellet and the pellet was then sonicated for 20 s.
The samples were stored at -200C until the assays for cGMP and cAMP
were performed, using specific enzyme-linked immunosorbent assays.
As a positive control, the effects of incubation of the platelets in the
presence of sodium nitroprusside (1 -1000 piM) were also assessed.
These experiments were performed on at least three separate prepara-
tions of platelets, each time in triplicate.
Rat platelet aggregation. The effects of aspirin and NCX 4215 on
rat platelet aggregation were studied ex vivo. Rats were given vehicle,
aspirin (100 mg/kg), or an equimolar dose of NCX 4215 (166 mg/
kg) or sodium salicylate (89 mg/kg) and three hours later were anesthe-
tized with ether. Blood was collected from the descending aorta and
platelet-rich plasma (PRP) was prepared (13). Aliquots (0.5 ml) of the
PRP were placed in the cuvette of a Payton platelet aggregometer and
continuously stirred at 37TC. After 1 min, adenosine diphosphate (ADP)
was added into the cuvette, and aggregation was monitored for the
following 5 min. ADP was tested at concentrations in the 2.5-40 [M
range. The responsiveness of platelets from these rats to collagen was
also assessed in the same manner. A concentration of collagen (25-
100 Itg/ml) causing 85-95% maximal aggregation was used in each
assay. For comparison to a nitric oxide donor, the effects of orally
administered sodium nitroprusside (145 mg/kg; equimolar to the 166
mg/kg dose of NCX 4215) on ADP- and collagen-induced platelet
aggregation were also assessed.
The effects of aspirin (100 mg/kg) and NCX 4215 (166 mg/kg)
on platelet aggregation induced by thrombin were assessed, at 1, 3, 6,
and 12 h after administration of the test drugs (n = 4-6 per group).
Various concentrations of thrombin (1- 100 U/ml) were tested for their
ability to induce aggregation of platelets from vehicle-treated rats, and
the concentration causing 85-95% maximal aggregation was used in
the experiments with platelets from aspirin- or NCX 4125-treated rats.
Results were then expressed as percent inhibition of aggregation relative
to platelets from vehicle-treated rats.
Thromboxane and prostaglandin synthesis. The synthesis of throm-
boxane by whole blood was determined using the method of Patrono et
al. (17). Groups of rats (n = 5 each) were given ASA (10-100 mg/
kg), NCX 4215 (30-300 mg/kg) or vehicle orally and were anesthe-
tized with ether 3 h later. Blood was drawn from the descending aorta
into a syringe and immediately 1 ml of the blood was transferred to a
glass tube. The tubes of blood were allowed to stand at 37°C for 45
min, after which they were centrifuged (1000 g; 10 min). The serum
was transferred to Eppendorf tubes then frozen at -20°C. Thromboxane
B2 concentrations in the serum samples were measured using a specific
enzyme-linked immunosorbent assay. An additional group of rats (n
= 5) received NCX 4215 (100 mg/kg) intraperitoneally, and 3 h later
blood was collected for determination of thromboxane synthesis, as
above.
A separate series of experiments was performed to determine the
effects of daily administration of aspirin (100 mg/kg) or an equimolar
dose ofNCX 4215 (166 mg/kg) for five days on thromboxane synthesis.
Three hours after the final (fifth) dose of the drugs or vehicle, blood
was collected and processed, as described above, for measurement of
thromboxane B2 synthesis.
To determine the extent of any inhibitory actions of NCX 4215
versus aspirin on gastric prostaglandin synthesis, a series of studies
were performed in which the capacity of this tissue to generate 6-keto
prostaglandin Fl. (the stable hydration product of prostacyclin) in vitro
was determined. Three rats were deprived of food but not water over-
night. They were then killed and the stomach removed. The corpus
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region of the stomach from each rat was then divided into approximately
equal sized pieces (- 100 mg) and randomly added to tubes containing
1 ml of sodium phosphate buffer (pH 7.4) alone, or containing aspirin
1, 10, 100, or 1000 1iM) or NCX 4215 (same concentrations). The
tissue samples were minced with scissors for 10 s, then the tubes were
placed in a shaking water bath (37TC) for 10 min. After centrifugation
(9000 g) for 3 min, the supernatants were frozen on dry ice then stored
at -70'C until an ELISA assay was performed to determine concentra-
tions of 6-keto PGF1,.
Gastric mucosal damage. Groups of rats (n = 5 each) were deprived
of food, but not water, for 18 h and were then given aspirin (10-120
mg/kg), NCX 4215 (30-300 mg/kg) or vehicle orally. The volume
of drug/vehicle administered was I ml/kg. Three hours later the rats
were killed and the stomach excised. An observer unaware of the treat-
ment the rats had received scored the severity of macroscopically visible
damage using a method described previously (18). This method in-
volves measuring the length of lesions in mm, then summing the lengths
of all lesions observed in each stomach. After scoring the gastric tissue
was fixed in neutral buffered formalin and processed by routine tech-
niques prior to embedding in paraffin, sectioning and staining with
hematoxylin and eosin. The slides were coded to avoid observer bias
prior to being examined under a light microscope.
An additional series of experiments examined the effects of aspirin
and NCX 4215 on the stomach after repeated administration over a two-
week period. Groups of five rats each received vehicle, aspirin (100
mg/kg) orNCX 4215 (166 mg/kg) orally each day. Three hours follow-
ing the final dose (on day 14), the rats were killed, the stomach exam-
ined and the severity of damage scored as described above.
Plasma salicylate levels. To determine if NCX 4215 was metabo-
lized to salicylate, a series of experiments were performed in which
groups of four rats each were anesthetized with ether 1, 3, 6, or 12 h
after oral administration of aspirin (100 mg/kg) or an equimolar dose
of NCX 4215 (166 mg/kg). Plasma salicylate concentrations were de-
termined spectrophotometrically (19) using a commercially available
kit. A standard curve was constructed using plasma spiked with sodium
salicylate in the 10-1000 jig/ml range, and similar concentrations of
aspirin and NCX 4215 were also tested in the assay. The assay did not
detect aspirin or NCX, while the detection of salicylate was linear over
the range of concentrations tested (r2 = 0.98; n = 6).
Systemic arterial blood pressure. Rats were anesthetized with ure-
thane (25%; 0.6 ml/100 grams body weight, i.p.) and a carotid artery
was cannulated for measurement of systemic arterial blood pressure.
After recording pressure for 15 min, vehicle, aspirin (100 mg/kg) or
an equimolar dose of NCX 4215 (166 mg/kg) or sodium nitroprusside
(145 mg/kg) was injected intravenously. Blood pressure was continu-
ously recorded for the ensuing three hours. Each group consisted of five
rats.
Materials. The assay kits for measurement of TXB2, 6-keto PGF1,,
cyclic GMP and cyclic AMP were obtained from Cayman Chemical
Company, Ann Arbor, MI. NCX 4215 (acetylsalicylic acid 4-(nitroxy) -
butylester) was provided by NicOx Ltd., London, England. Adenosine
diphosphate, rabbit hemoglobin, sodium nitroprusside, human thrombin
and the assay kit for plasma salicylate were obtained from Sigma Chemi-
cal Co. (St. Louis, MO). Type 6 collagen was obtained from Hormon
Chemie, Munich, Germany. Carboxymethylcellulose was obtained from
British Drug House Ltd. (Poole, England). All other reagents were
obtained from Fisher Scientific Ltd., Edmonton, Alberta.
Statistical analysis. All data are expressed as the mean±SE. Com-
parisons of two groups of data were performed using the Student's t
test, whereas comparisons among more than two groups of data were
performed using a one way analysis of variance followed by a Student-
Newman-Keuls post-hoc test (Instat software package, GraphPad Soft-
ware, San Diego, CA). With all such analyses, an associated probability
(P value) of < 5% was considered significant.
Results
In vitro human platelet studies. Addition of aspirin to human
platelets resulted in concentration-dependent inhibition of
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Figure 2. Effects of aspirin and NCX 4215 on thrombin-induced human
platelet aggregation in vitro. Each point represents the mean±SE of six
experiments. The platelets were incubated with the test drugs for 10
min before stimulation with thrombin, and aggregation was monitored
for 5 min thereafter. Results are expressed as a percent inhibition of
aggregation relative to the platelets pretreated with the vehicle.
thrombin-induced aggregation (Fig. 2). NCX 4215 also concen-
tration-dependently inhibited platelet aggregation, but this com-
pound was more potent in this action than aspirin. Indeed, the
IC50 for NCX 4215 (0.34 mM) was about one-seventh that for
aspirin (2.24 mM).
Chemiluminescence detection of nitric oxide concentrations
demonstrated that incubation of platelets with aspirin at concen-
trations of 1-1000 iM did not result in significant liberation
of nitric oxide (Fig. 3). However, incubation of platelets with
NCX 4215 at concentrations of 100 and 1000 MuM resulted in
significant liberation of nitric oxide. This release was apparent
after only 1 min of incubation of the drug with platelets. While
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Figure 3. Nitric oxide release, determined by chemiluminescence, from
aspirin and NCX 4215 incubated with human platelets. Significant
amounts of nitric oxide were released from NCX 4215 at concentrations
of 100 and 1000 ILM when incubated with the platelets for 1 or 10 min
(** P < 0.01, *** P < 0.001: NCX 4215-treated platelets [both
incubation times] versus the platelets treated with vehicle). Nitric oxide
release was not detectable when NCX 4215 was incubated in the absence
of platelets.
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Table L Effects ofAspirin, NCX 4215, and Sodium Nitroprusside
on Platelet cAMP and cGMP Levels
Incubation
Group Time cAMP cGMP
min pg/ml pg/ml
Vehicle 1 74.5±14.5 5.44±0.98
ASA (1 kM) 1 58.8±9.0 7.41±2.58
ASA (10 /M) 1 57.1±6.6 5.42±0.91
ASA (100 MM) 1 47.8±3.1 6.80±0.41
ASA (1 mM) 1 157.2±21.5§ 10.18± 1.58
NCX-4215 (1 MM) 1 56.3± 11.6 12.93±6.63
NCX-4215 (10 gm) 1 73.2±29.5 6.24±2.19
NCX-4215 (100 MM) 1 66.5±14.4 34.13±17.73
NCX-4215 (1 mM) 1 150.3±17.5* 55.91±42.07
Nitroprusside (1 MM) 1 95.2±3.2 5.51±0.32
Nitroprusside (10 /uM) 1 94.1±10.0 9.77±2.98
Nitroprusside (100 MM) 1 57.5±15.1 10.80±1.96
Nitroprusside (1 mM) 1 197.6±3.0§ 42.71±9.02
Vehicle 10 56.0±16.6 5.09±1.08
ASA (1 MM) 10 58.9±7.8 6.05±0.81
ASA (10 Mm) 10 82.2±3.2 6.47±1.41
ASA (100 MM) 10 71.8±21.7 5.66±1.36
ASA (1 mM) 10 111.8±16.9 13.16±3.24
NCX-4215 (1 MM) 10 56.3±11.6 6.17±1.07
NCX-4215 (10 MM) 10 73.2±29.5 17.21±10.06
NCX-4215 (100 MM) 10 66.5±14.4 45.54±4.28*
NCX-4215 (1 mM) 10 150.3±17.5* 77.77±5.88§
Nitroprusside (1 MLM) 10 37.8±2.6 7.6±2.23
Nitroprusside (10 MM) 10 55.2±13.0 42.89±2.81*
Nitroprusside (100 MM) 10 46.3±11.8 156.30±4.41§
Nitroprusside (1 mM) 10 161.8±6.1§ 370.18±32.32§
* P < 0.05, * P < 0.01, § P < 0.001 compared with the corresponding
vehicle-treated group (ANOVA and Student-Newman-Keuls Multiple
Comparison Test). Results are expressed as mean±SE (n = 3-6 per
group).
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Figure 4. Effects of preincubation of human platelets with 10MUM hemo-
globin on anti-aggregatory effects of aspirin and NCX 4215. Platelet-
rich plasma was preincubated with hemoglobin for 2 min, then incubated
with aspirin (ASA), NCX 4215 or vehicle for 10 min (n = 6). The
platelets were then stimulated with thrombin and aggregation was moni-
tored for 5 min. Results are expressed as percent inhibition of aggrega-
tion relative to the platelets pretreated with the vehicle but not hemoglo-
bin. Hemoglobin did not significantly affect the extent of thrombin-
induced aggregation in platelets pretreated with vehicle or in platelets
pretreated with aspirin. However, hemoglobin did significantly reduce
the anti-aggregatory effects of NCX 4215 (*P < 0.05 compared to that
aspirin group not treated with hemoglobin; 6P < 0.05 compared with
the corresponding group not treated with hemoglobin.
inhibited thrombin-induced platelet aggregation by 40±4% and
63+1%, respectively.
Hemoglobin did not significantly affect the extent of platelet
aggregation observed after stimulation with thrombin, as re-
ported previously (13). Similarly, hemoglobin did not signifi-
liberation of nitric oxide from this compound occurred when
the drug was incubated with platelets, nitric oxide release was
not detectable from samples of the drug incubated with buffer
alone.
Exposure of human platelets to aspirin at concentrations of
1 to 1000 MM did not significantly affect intracellular cyclic
GMP levels during the first minute of exposure (Table 1).
Cyclic AMP levels were unaffected during this period by expo-
sure to any of the test drugs at concentrations in the I to 100 /LM
range. However, all three test drugs, at a 1 mM concentration,
significantly elevated platelet cAMP levels. When exposure to
the test drugs was extended to 10 min, aspirin did not exert any
significant effect on cGMP or cAMP levels. However, both
NCX 4215 (100 and 1000 MM) and sodium nitroprusside (10,
100, and 1000 MM) markedly elevated cGMP levels. The eleva-
tions in platelet cGMP levels were substantially greater with
sodium nitroprusside than with NCX 4215. This corresponds
to enhanced anti-aggregatory effects of sodium nitroprusside
versus NCX 4215 on thrombin-induced platelet aggregation. At
concentrations of 10 and 100 MM, NCX 4215 inhibited throm-
bin-induced platelet aggregation by 2±1% and 25±7%, respec-
tively, while the same concentrations of sodium nitroprusside
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Figure 5. Effects of orally administered aspirin (ASA) and NCX 4215
on macroscopically assessed gastric damage severity. The dotted line
shows the mean gastric damage score in vehicle-treated rats. Each group
consisted of five rats. Damage was assessed three hours after oral admin-
istration of the compounds by an observer unaware of the treatments
the rats had received. Asterisks denote a significant (P < 0.001) differ-
ence compared to the vehicle-treated group.
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cantly affect the inhibition of platelet aggregation induced by
aspirin at concentration of 10 to 1000 4ttM (Fig. 4). However,
hemoglobin significantly reduced the anti-aggregatory activity
of the NCX 4215 (100 and 1000 AM). Hemoglobin also sig-
nificantly attenuated the anti-aggregatory effect of sodium nitro-
prusside (100 ,M), reducing its inhibition of thrombin-stimu-
lated aggregation from 63±1% to 33±3% (P < 0.01).
In vivo rat studies: gastric damage. Oral administration of
aspirin resulted in the formation of extensive hemorrhagic le-
sions in the stomach. These lesions were usually linear, running
along the crests of rugal folds, and were observed primarily in
the corpus region. Histologically, the lesions were found to be
confined to the mucosal layer, not penetrating the muscularis
mucosae. The severity of gastric damage induced by aspirin
increased in a dose-dependent manner (Fig. 5). In contrast,
NCX 4215 did not produce significant gastric damage at any
of the doses tested (30-300 mg/kg). The absence of damage
following NCX 4215 administration was confirmed histologi-
cally.
Similar differences in gastric damage were observed in the
study in which rats were killed various times after drug adminis-
tration. In rats killed 1, 3, 6 and 12 h after administration of
aspirin ( 100 mg/kg; n = 4 per group), the mean damage scores
were: 50.5 ±4.6, 54.5±11.3, 62.0±15.6 and 42.3±16.8. Damage
was not observed in rats examined at the same times after
administration of an equimolar dose of NCX 4215 (P < 0.01
at all time points). Moreover, following daily administration of
these doses of aspirin and NCX 4215 for 14 d, there was a clear
difference between the drugs in terms of gastric damage. In the
aspirin-treated rats, there was evidence of persistent hemor-
rhagic lesions and scar tissue where lesions had healed. Histo-
logically the lesions involved the full depth of the mucosa. The
mean damage score was 26.4±0.9 (n = 5). However, in the
rats treated with NCX 4215 (n = 5), damage was not detectable,
either macroscopically or histologically.
In vivo rat studies: blood pressure. Intravenous administra-
tion of aspirin (100 mg/kg) or an equimolar dose ofNCX 4215
(166 mg/kg) to anesthetized rats did not significantly affect
systemic arterial blood pressure, which was monitored for the
NCX 4215
Vehicle
ASA
Figure 6. Effects of intravenous administration of aspirin
(100 mg/kg) or equimolar doses of NCX 4215 (166 mg/
kg) or sodium nitroprusside (145 mg/kg) on systemic arte-
rial blood pressure in anesthetized rats. All rats receiving
intravenous sodium nitroprusside died within 5 min of its
administration. Aspirin and NCX 4215 did not significantly
affect systemic arterial blood pressure relative to the vehi-
cle-treated group.
ensuing 3 h (Fig. 6). However, administration of an equimolar
dose of sodium nitroprusside (145 mg/kg) led within 5 min to
extensive hypotension and death.
In vivo rat studies: plasma salicylate levels. Oral adminis-
tration of aspirin (100 mg/kg) resulted in the appearance of
salicylate in plasma within one hour (Fig. 7). The levels of
salicylate in plasma reached a peak at 3 h post-administration
(- 150 tg/ml), remained at a similar level at 6 hours post-
administration, and had declined to 60 ,ug/ml by 12 h after
administration. Oral administration of an equimolar dose of
NCX 4215 also resulted in the appearance of salicylate in
plasma, but it was not detectable until 3 h after administration
and was virtually all eliminated by 12 h after administration.
Evaluation of the areas under the curves shown in Fig. 7 re-
vealed that the amount of salicylate generated from NCX 4215
was 27% of that generated by an equimolar dose of aspirin.
Neither aspirin nor NCX 4215 could be detected in this assay
at concentrations in the 10-1000 j.g/ml range.
Ex vivo rat studies: platelet aggregation. Aspirin and NCX
4215 inhibited ex vivo platelet aggregation induced by thrombin
(Fig. 7). Platelets from rats treated 1-3 h earlier with aspirin
(100 mg/kg) or an equimolar dose of NCX 4215 were signifi-
cantly less responsive to thrombin than vehicle-treated controls.
At 6 hours post-administration, the NCX 4215 continued to
significantly inhibit thrombin-induced aggregation, although the
effect was much more variable than at the earlier time points.
At 12 h post-administration, neither NCX 4215 nor aspirin sig-
nificantly inhibited aggregation.
Oral administration of aspirin (100 mg/kg) also signifi-
cantly depressed the responsiveness of platelets, harvested 3
hours later, to stimulation by ADP or collagen (Fig. 8). Oral
administration of an equimolar dose of sodium salicylate did
not significantly affect platelet aggregation responses to ADP
or collagen, when compared to platelets from vehicle-treated
rats. However, platelets from rats treated orally with NCX 4215
were significantly less responsive to both ADP and collagen.
In fact, the effects of NCX 4215 on platelet aggregation were
not significantly different from those of aspirin. When platelets
were harvested from rats 12 h after administration of the test
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Figure 8. Effects of orally administered aspirin, salicylate, NCX 4215
or vehicle on platelet aggregation in response to stimulation with ADP
or collagen. Platelets were collected from rats 3 h after administration
of the drugs. Aspirin was given at a dose of 100 mg/kg, and the other
test drugs were given at doses equimolar to the aspirin dose. Asterisks
denote significant inhibitory effects of aspirin and NCX 4215 relative
to the other two groups (* P < 0.05, ** P < 0.01, *** P < 0.001).
Each bar represents the mean±SE for at least five rats per group.
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Figure 7. (Upper panel) Inhibition of thrombin-induced platelet aggre-
gation by aspirin and NCX 4215. Rats received aspirin (100 mg/kg)
or an equimolar dose of NCX 4215 (166 mg/kg) orally and blood was
collected 1-12 h later. Platelet aggregation in response to thrombin was
assessed (see Methods) and the results expressed as percent inhibition
of aggregation relative to that seen in platelets harvested from rats
treated with the vehicle. tP < 0.05 compared to vehicle-treated controls.
Each point represents the mean±SE for 4-6 rats. (Lower panel ) Plasma
salicylate levels up to 12 h following oral administration of aspirin (100
mg/kg) or an equimolar dose of NCX 4215 (166 mg/kg). (* P < 0.05,
* *P < 0.01 compared with the NCX 4215 group). Each point repre-
sents the mean±SE for four rats.
drugs, aspirin continued to completely inhibit the aggregation
induced by collagen, while NCX 4215 no longer exhibited any
effect.
When administered orally at an equimolar dose to that of
NCX 4215 in the studies described above, sodium nitroprusside
had no significant effect on platelet aggregation induced by
ADP or collagen. All of the rats treated with sodium nitroprus-
side at this dose (145 mg/kg; n = 3) were lethargic and in a
state of semi-consciousness within 30 min of its administration.
At the time of drawing the blood samples, these rats exhibited
profound engorgement of the mesenteric circulation.
Ex vivo rat studies: thromboxane andprostaglandin synthe-
sis. Oral administration of aspirin resulted in a dose-dependent
suppression of thromboxane synthesis by whole blood, with the
100 mg/kg dose inhibiting by 99% (Fig. 9). NCX 4215, at
doses of 30 to 300 mg/kg, was without significant effect on
thromboxane synthesis. NCX 4215 (100 mg/kg) also had no
significant effect on thromboxane synthesis when administered
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Figure 9. Effects of orally administered aspirin or NCX 4215 on throm-
boxane synthesis by rat blood. Blood was collected 3 h after administra-
tion of the test drugs, or vehicle. Production of thromboxane B2 by
whole blood was measured at the end of a 45-min incubation period.
While aspirin significantly inhibited thromboxane synthesis (* P < 0.05,
* * * P < 0.001 ), NCX 4215 had no effect. Each bar represents the
mean±SE for five rats per group.
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Table IH. Effects of Daily Administration of Aspirin or NCX 4215
for 5 d on Thromboxane Synthesis by Rat Whole Blood
Treatment Thromboxane B2 (ng/ml)
Vehicle 459±28
Aspirin (20 mg/kg) 17±3*
NCX 4215 (33 mg/kg) 505±23
Aspirin (50 mg/kg) 6±1*
NCX 4215 (83 mg/kg) 398±22
Production of thromboxane B2 by whole blood was measured at the end
of a 45-min incubation period. * P < 0.01 compared with the vehicle-
treated group.
intraperitoneally (mean TXB2 synthesis of 310±14 ng/ml, ver-
sus 278±+20 ng/ml in controls).
Daily administration of aspirin for 5 d at doses of 20 and 50
mg/kg resulted in near-complete suppression of thromboxane
synthesis by whole blood (Table II). However, administration
of equimolar doses of NCX 4215 was without significant effect
on thromboxane synthesis.
As shown in Table HI, incubation of gastric tissue in the
presence of aspirin resulted in a concentration-dependent (1-
1000 [Mg/ml) inhibition of 6-keto prostaglandin Fl. synthesis.
However, equimolar concentrations of NCX 4215 had no sig-
nificant effect on gastric prostaglandin synthesis.
Discussion
The anti-thrombotic actions of aspirin are related to its ability
to suppress thromboxane synthesis, by inhibiting the enzyme
cyclo-oxygenase in platelets (2). However, suppression of
cyclo-oxygenase is associated with significant toxicity in the
gastrointestinal tract (20) and, less frequently, in the kidney
(21 ). This toxicity limits the utility of aspirin for long-term use
as an anti-thrombotic agent. In this study we have tested the
hypothesis that addition of a nitric oxide-releasing moiety to
aspirin would yield a compound that retained its anti-thrombotic
actions, but had reduced gastrointestinal toxicity. Our initial
Table III. Effects of Aspirin and NCX 4215 on Gastric
Prostaglandin Syntheses in Vitro
Treatment 6-keto Prostaglandin F1. (pg/mg)
Vehicle 1121±141
Aspirin (1 Mg/ml) 1180± 193
NCX 4215 (1.66 1g/ml) 1321±214
Aspirin (10 1g/ml) 558+218k
NCX 4215 (16.6 Mg/ml) 1451±+229
Aspirin (100 Mg/ml) 531± 92*f
NCX 4215 (166 Mg/ml) 1202±212
Aspirin (1000 Mg/ml) 145±23**
NCX 4215 (1660 Mg/ml) 966±228
* P < 0.05 compared to the vehicle-treated group. * P < 0.05 compared
with the corresponding (equimolar) dose of NCX 4215. n = 3-6 per
group. Tissues were incubated in vitro in the presence of the test drugs
or vehicle.
expectation was that the nitric oxide released from such a com-
pound would protect the gastrointestinal tract from the damag-
ing consequences of suppression of cyclo-oxygenase activity,
as we have previously found with similar derivatives of flurbi-
profen, ketoprofen and diclofenac (9-1 1). However, the aspirin
derivative, NCX 4215, was found not to inhibit cyclo-oxygenase
activity, but still to have significant inhibitory effects on platelet
aggregation induced by thrombin (human platelets), collagen
or ADP (rat platelets). In the human platelet studies, NCX
4215 was significantly more potent than aspirin as an inhibitor
of aggregation. This augmented anti-aggregatory effect ap-
peared to be related to release of nitric oxide from NCX 4215,
since this compound significantly elevated platelet cGMP levels
at concentrations that inhibited platelet aggregation, whereas
aspirin did not, and because hemoglobin significantly attenuated
the anti-aggregatory effects of NCX 4215. Hemoglobin is a
well characterized scavenger of nitric oxide ( 15 ) and has been
shown in previous studies of this type to suppress nitric oxide-
mediated inhibition of platelet aggregation (13). Studies using
chemiluminescent detection of nitric oxide confirmed that NCX
4215 released nitric oxide, but only when the drug was incu-
bated with platelets (i.e., no spontaneous release). Nitric oxide
release was observed within 1 min of addition of the compound
to human platelets. These observations are consistent with the
hypothesis that NCX 4215 must undergo metabolism by the
platelet before releasing nitric oxide. In the case of platelet
cGMP levels, statistically significant increases were not appar-
ent with NCX 4215 after 1 min of incubation, but were observed
with the 10-min incubation. Sodium nitroprusside, a well char-
acterized nitric oxide donor, also increased platelet cGMP levels
after 10 min incubation, but not after 1 min.
In light of the observation that NCX 4215 does not inhibit
cyclo-oxygenase activity (i.e., prostaglandin and thromboxane
synthesis), it is perhaps not surprising that this compound did
not produce significant damage in the stomach. There is abun-
dant evidence supporting the hypothesis that suppression of
gastric prostaglandin synthesis is a critical component of the
ulcerogenic properties of aspirin and NSAIDs (20). Even after
daily administration of this compound for 14 d, gastric injury
was not observed. Whether or not this compound will induce
gastric injury when administered over a more prolonged period
of time, or in other species, is the subject of ongoing studies.
Nitric oxide donors have been extensively characterized as
inhibitors of platelet aggregation in vitro (12), but not in ex
vivo or in vivo studies. One problem with the use of nitric oxide
donors for anti-thrombotic applications is that drugs such as
sodium nitroprusside and glyceryl trinitrate relax vascular
smooth muscle, thereby reducing systemic blood pressure.
Whether or not doses of nitric oxide donors below the threshold
of effects on systemic blood pressure would release or generate
sufficient nitric oxide to inhibit platelet aggregation has not been
reported. It is noteworthy that at a dose that caused significant
inhibition of collagen- and ADP-induced rat platelet aggregation
ex vivo, intravenously administered NCX 4215 did not signifi-
cantly affect systemic arterial blood pressure. On the other hand,
an equimolar dose of sodium nitroprusside had no effect on
platelet aggregation, but when given intravenously, caused pro-
found hypotension and death within minutes. It is possible that
the aspirin derivative releases nitric oxide at a slower rate and/
or in lower amounts that standard nitric oxide donors. Indeed,
NCX 4215 caused a much smaller increase in platelet cGMP
levels than that caused by an equimolar concentration of sodium
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nitroprusside. While our in vitro data suggest that NCX 4215
inhibits platelet aggregation at least in part through the release
of nitric oxide, we cannot rule out the possibility that in vivo,
the inhibition of platelet aggregation by this compound may
occur through mechanisms unrelated to the generation of nitric
oxide.
Aspirin is increasingly being used on a chronic basis as an
anti-thrombotic agent. There is convincing evidence for benefi-
cial effects of aspirin in the prevention of stroke and myocardial
infarction (1, 6, 22, 23). Low doses of aspirin, when used over
several days, are capable of profoundly suppressing platelet
thromboxane synthesis and therefore platelet activation, while
having only a modest inhibitory effect on gastric prostaglandin
synthesis (24). Because of this, the incidence of gastrointestinal
bleeding with low dose aspirin is much less than that observed
with anti-inflammatory doses of aspirin or other NSAIDs. How-
ever, there remains a significant risk of gastrointestinal bleeding
and hemorrhagic stroke with low dose aspirin (23, 25, 26), as
well as adverse effects related to blood pressure control in pa-
tients with essential hypertension (27, 28) and heart failure
(29). Therefore, as recently concluded by Patrono (1), despite
the effectiveness of aspirin in preventing between 20 and 33%
of "all important cardiovascular events," there remains a need
for effective antithrombotic drugs which carry a lower risk of
adverse effects. Since NCX 4215 is capable of inhibiting platelet
aggregation at least as effectively as aspirin without affecting
cyclo-oxygenase activity, it does not cause damage to the gastric
mucosa. Since this compound does not suppress thromboxane
synthesis, even when given daily for five days, it can be con-
cluded that it is not metabolized to yield aspirin. It should be
noted that even a conversion of - 5% of the administered NCX
4215 to aspirin would have been sufficient to be detected
through its ability to suppress thromboxane synthesis. The mea-
surement of plasma salicylate levels using an assay that did not
detect aspirin or NCX 4215 revealed that the majority (- 73%)
of the NCX 4215 administered was not converted to salicylate.
Taken together with the observation that NCX 4215 was much
more active than salicylate in terms of inhibiting platelet aggre-
gation, we can rule out the possibility that the compound acted
purely as a pro-drug for salicylate. While further studies are
required to fully understand the metabolism and pharmacokinet-
ics of this compound, NCX 4215 serves as a useful prototype
to test the hypothesis that a nitric oxide donor can exert anti-
thrombotic effects without untoward effects on systemic blood
pressure or on the gastric mucosa.
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